Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaA sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsEmerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLPhiladelphia chromosome-positive acute lymphoblastic leukemia.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsPhiladelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Current and future management of Ph/BCR-ABL positive ALL.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study.Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.Overexpression of dominant-negative Ikaros 6 isoform is associated with resistance to TKIs in patients with Philadelphia chromosome positive acute lymphoblastic leukemiaTyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.Redefining transplant in acute leukemia.Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.Management of older adults with acute lymphoblastic leukemia: challenges & current approaches
P2860
Q27025242-490387DB-80CA-4545-9605-C8EDA2F607C4Q33822032-44EECF49-6E22-4B64-A546-A484B0DCE86EQ34031967-5BA89E5C-3B29-48D7-80F0-62B8C4B6C458Q34378360-C817DF1D-2D61-4817-A691-C717B6643123Q36461915-4DEFE72B-5DE1-4790-B931-E77A3005E5E9Q36758604-422E32F1-90E6-44DD-A1E0-E7D2B9909F6DQ37152745-A8EA9EB9-C374-420B-9502-FDB7A863E0ABQ37376595-70F2F678-9E54-49B1-8CBB-B76A1E087221Q37613888-86BDA6DC-A70A-433B-BEF7-1EB1D60D6F11Q37630453-040088F0-44E6-49EF-A991-B4D72F5779BBQ37632798-E97EC269-075D-4BC9-B09D-92DD8FC73D4EQ37650203-3D08853C-7144-48FD-BCB0-EF89812093C6Q37810967-A4570A4C-6E18-40E3-95B5-C0C26BFA46B1Q37836938-C74191F1-EA87-48CF-975D-188B157BEF11Q37862648-53177DBB-256E-4247-A27E-7B00B030AE5AQ37875969-56D1DE4F-9D3B-4C06-AC8B-B20AB32ACCDFQ37931235-074F7CF3-9887-433B-8C85-98B482417322Q38016343-C4F7FCA3-2A7E-4FCE-8926-C02DF8EC057EQ38044901-F22BAD00-B9E9-491D-B481-CD24582B4B72Q38087930-41343A66-74F1-4B4C-9B7A-806A3B599601Q38165148-B3184E5A-27FD-4BE8-85B8-9F5585081AD9Q38194585-B154711F-9E0D-4E8B-838F-ED21D21656EFQ38207017-490EA308-5DC5-419E-A787-AB40EA4B0D30Q38739574-FF29AF77-A981-412D-9EAD-667E03313C53Q39315839-2FC9F5A8-6EDA-41C1-84DE-EF7326EC89F0Q40178701-46A4B778-A66F-4FEE-8D15-0A6BCD4877CAQ41594071-B7D888C0-2A22-49EF-B593-B3289DAF9A82Q41600141-05E47A69-A49F-4F11-A576-3ABE7AF2CF70Q41843107-5FA5EC20-ED70-453D-9EE4-34369EEAEA62Q42376333-94009B53-FD9F-4F57-AB4A-852D29EF1781Q43175147-1FD304B3-C491-42B2-A303-1A60283A16A9Q44657508-7D71F4C5-DA03-450A-AF2F-82E7E0A0B4E8Q46236668-3D333651-0F8A-4BBA-B422-DB5E2702D4F4Q46341511-98CED2B8-B43A-4321-A83A-1F22858C27DAQ47710825-855E74EA-0635-47E6-A4C1-CBF1C8CD2A1BQ47774455-79DB4A5D-0609-47B9-A7E1-75F70C88F384Q50880138-81CF5A17-E910-4DF8-A6C8-8A82A435323FQ52563633-6180EB9F-877D-4CB6-96DB-4234D76FE320Q54330255-8449E78C-6EBF-4CC4-9F1E-E45A5B3E79ABQ57301411-A75F37C2-4A58-4797-B3DD-A6E411C7410F
P2860
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
description
im Juli 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 13 July 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2006
@uk
name
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@en
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@nl
type
label
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@en
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@nl
prefLabel
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@en
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@nl
P2093
P2860
P921
P356
P1433
P1476
Imatinib and methylprednisolon ...... ults of the GRAALL AFR09 study
@en
P2093
Berthaud P
Bilhou-Nabera C
Caillères S
Castaigne S
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404320
P407
P577
2006-07-13T00:00:00Z